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Abstract
Background: Hepatocyte growth factor (HGF) and its receptor c-MET are commonly expressed
in malignant gliomas and embryonic neuroectodermal tumors including medulloblastoma and
appear to play an important role in the growth and dissemination of these malignancies. Dependent
on cell context and the involvement of specific downstream effectors, both pro- and anti-apoptotic
effects of HGF have been reported.
Methods: Human medulloblastoma cells were treated with HGF for 24–72 hours followed by
death receptor ligand TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) for 24
hours. Cell death was measured by MTT and Annexin-V/PI flow cytometric analysis. Changes in
expression levels of targets of interest were measured by Northern blot analysis, quantitative
reverse transcription-PCR, Western blot analysis as well as immunoprecipitation.
Results: In this study, we show that HGF promotes medulloblastoma cell death induced by TRAIL.
TRAIL alone triggered apoptosis in DAOY cells and death was enhanced by pre-treating the cells
with HGF for 24–72 h prior to the addition of TRAIL. HGF (100 ng/ml) enhanced TRAIL (10 ng/
ml) induced cell death by 36% (P < 0.001). No cell death was associated with HGF alone. Treating
cells with PHA-665752, a specific c-Met receptor tyrosine kinase inhibitor, significantly abrogated
the enhancement of TRAIL-induced cell death by HGF, indicating that its death promoting effect
requires activation of its canonical receptor tyrosine kinase. Cell death induced by TRAIL+HGF
was predominately apoptotic involving both extrinsic and intrinsic pathways as evidenced by the
increased activation of caspase-3, 8, 9. Promotion of apoptosis by HGF occurred via the increased
expression of the death receptor DR5 and enhanced formation of death-inducing signal complexes
(DISC).
Conclusion: Taken together, these and previous findings indicate that HGF:c-Met pathway either
promotes or inhibits medulloblastoma cell death via pathway and context specific mechanisms.
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Background
Hepatocyte growth factor (HGF) is a multifunctional
cytokine that was originally described as a mesenchymal-
derived factor that regulates cell growth, cell motility,
morphogenesis and angiogenesis [1-3] through activation
of its receptor, the transmembrane tyrosine kinase
encoded by the c-Met proto-oncogene [4]. HGF and c-Met
are often co-expressed or over-expressed in a variety of
human malignancies including glioblastoma and medul-
lablastoma; and their expression level correlates with poor
prognosis [5-8]. The multifunctional effects of HGF:c-Met
signaling in tumor cells are mediated by a network of sig-
nal transduction pathways including mitogen-activated
protein kinase (MAPK) and phosphoinositide 3-kinase
(PI3K). Paradoxically and dependent on cell context and
the involvement of specific downstream effectors, both
pro- and anti-apoptotic effects of HGF have been reported
[9]. It is well documented that c-Met kinase-dependent
signaling is able to counteract apoptosis induced by DNA-
damage through the initiation of survival signals such as
the PI3K-Akt, MAPK and NFκB pathways [10-13]. In addi-
tion, c-Met can bind to and sequester Fas via a kinase-
independent mechanism in several types of cells, includ-
ing epithelial and glioblastoma cells, and thereby prevent
cell death induced by death receptor ligand [14,15]. On
the other hand, the mechanisms by which HGF:c-Met
exerts pro-apototic effects are not fully understood. It has
been reported that HGF:c-Met signaling induces or sensi-
tizes apoptotic cell death in a number of cell lines includ-
ing ovarian carcinoma cell, breast carcinoma cell, mouse
sarcoma cell and mouse hepatocarcinoma cell [16-19].
Although the anti-apoptotic functions of the HGF:c-Met
pathway appear to predominate in most biological sys-
tems, pro-apoptotic responses have been observed and
could contribute to the balance between cell death and
survival during the initiation and progression of certain
malignancies.
Embryonic neuroectodermal malignancies such as medul-
loblastoma are among the most common and aggressive
childhood brain tumors, and are associated with high
rates of morbidity and mortality. Significant improve-
ments in survival have been achieved by treating patients
early with combinations of radiation and chemotherapy
(for reviews, see [20-22]). However, aggressive therapy
during critical periods of CNS development results in con-
siderable neurocognitive toxicity and durable responses in
patients with recurrent medulloblastoma remain disap-
pointing. Improving our understanding of medulloblast-
oma cell death and survival mechanisms and developing
new strategies to overcome the inherent resistance of
medulloblastoma cells to death signals could have signif-
icant impacts on survival and neurocognitive outcomes
[23,24].
Induction of selective cancer cell death is the goal of many
cancer therapies [25]. Apoptotic cell death can be initiated
by either the intrinsic mitochondrial pathway or the
extrinsic death receptor pathway [26]. Tumor necrosis fac-
tor (TNF)-related apoptosis-inducing ligand (Apo2L/
TRAIL) has the potential to initiate death receptor path-
ways in malignant tissues while sparing normal tissues
[27]. DR4 and DR5 are members of the TRAIL receptor
superfamily sharing conserved cytoplasmic death
domains essential for inducing apoptosis. Upon binding
to TRAIL, DR4 and DR5 recruit the adapter molecule Fas-
associated death domain (FADD), which through its
death domain interacts with pro-caspases-8 and -10 to
form a death-inducing signaling complex (DISC). DISC
then stimulates the proteolytic activation of the caspases-
8 and -10, initiating a cascade of downstream caspase acti-
vation which leads to apoptosis [28-30]. Nevertheless,
TRAIL does not yet offer a viable solution to brain cancer
therapy since many brain tumors display complete or par-
tial-resistance to death receptor agonists [24,31,32].
Earlier work by our laboratory and others has shown that
human medulloblastomas frequently express HGF, c-Met
and molecular constituents of the extrinsic (death recep-
tor) apoptosis pathway [7,33]. This study examines the
interactions between HGF:c-Met signaling and medullob-
lastoma cell death/apoptosis in response to TRAIL. We
found that in a representative medulloblastoma cell line,
HGF promotes TRAIL-induced medulloblastoma cell
death. We further examined the mechanism by which
HGF exert pro-apoptotic effect. We demonstrate that the
enhanced cell death response to TRAIL results from HGF-
mediated DR5 over-expression and increased death-
inducing signaling complex formation.
Methods
Reagents
All reagents were purchased from Sigma (St. Louis, MO)
unless otherwise stated. Drugs were made in stock and
diluted in cell culture medium. Recombinant human
TRAIL was purchased from Millipore/Chemicon (Biller-
ica, MA). Hepatocyte growth factor (HGF) was a gift from
Genentech, Inc. (San Francisco, CA). The JNK pathway
inhibitor CEP-11004 was kindly provided by Cephalon
Inc. (West Chester, PA) [34]. The c-Met kinase inhibitor
PHA-665752 was kindly provided by Pfizer, Inc. (La Jolla,
CA) [35]. Caspase 3, 8, 9 inhibitors were purchased from
Calbiochem (San Diego, CA).
Cell culture
Medulloblastoma cell line DAOY was originally pur-
chased from American Type Culture Collection (Rock-
ville, MD). DAOY cells were grown in Zinc Optimum
medium (Gibco, Rockville, MD) supplemented with 10%
fetal bovine serum (FBS, Cellegro, Washington, DC) andBMC Cancer 2008, 8:325 http://www.biomedcentral.com/1471-2407/8/325
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500  μg/ml penicillin-streptomycin (Gibco). Cells were
grown at 37°C in a humidified incubator with 5% CO2.
Cell viability assay
Cell viability was measured by MTT (3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. Cells
were plated at 5,000 cells/well in 24-well tissue culture
plates. After treatment, MTT was added to each well at a
final concentration of 150 μg/mL, and the cells were incu-
bated for 1–2 h at 37°C. The medium was then removed,
and the cell layer was dissolved with dimethyl sulfoxide
(DMSO). The formazen reaction product was quantified
spectrophotometrically at 570 nm using a Spectra MAX
340pc plate reader (Molecular Devices, Sunnyvale, CA,
USA). The results are expressed as the percentage of
absorbance measured in control cultures after subtracting
the background absorbance from all values.
Flow cytometry analysis
Apoptosis was quantified using the Annexin V-FITC apop-
tosis detection kit (BD Biosciences, San Diego, CA) via the
manufacturer's instructions. Briefly, cells were
trypsinized, pelleted by centrifugation, and resuspended
in Annexin V binding buffer (150 mM NaCl, 18 mM
CaCl2, 10 mM HEPES, 5 mM KCl, 1 mM MgCl2). FITC-
conjugated Annexin V (1 μg/ml) and propidium iodide
(PI, 50 μg/ml) were added to cells and incubated for 30
min at room temperature in the dark. To quantify cell sur-
face DR4 and DR5, cells were harvested by trypsinization
and centrifugation. The suspended cells were directly
incubated with PE-conjugated anti-DR4 or anti-DR5 anti-
body for 30 min (1:20, EBiosciences, San Diego, CA).
Non-immune mouse IgG was used as the negative con-
trol. Analyses were performed on a FACscan (Becton-
Dickinson, Mountain View, CA). Data were analyzed with
CellQuest software (Becton-Dickinson).
Western blot analysis
All primary antibodies used for Western blot analysis were
obtained from Cell Signaling Technology (Beverly, MA)
unless otherwise stated and concentrations used were
according to the manufacturers' recommendations. All
the secondary antibodies conjugated to horseradish per-
oxidase were purchased from Jackson Immunoresearch
Laboratories (West Grove, PA) and were used at a 1:1000
dilution. Briefly, cells were lysed with RIPA buffer (50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% Na-
deoxycholate) containing 1× protease and phosphatase
inhibitor cocktail (Calbiochem). After sonication for 15 s,
the suspensions were centrifuged at 3,000 g for 10 min-
utes. Protein concentrations were determined using the
Coomassie Protein Assay Reagent (Pierce, Rockford, IL).
Thirty micrograms of protein were subjected to 4%–20%
gradient SDS-PAGE (Lonza, Pittsburgh, PA) and then
transferred to nitrocellulose membranes (Amersham,
Pittsburgh, PA) for 1 h. The membranes were then incu-
bated with 5% non-fat dry milk (Carnation, Nestle Food
Co., Glendale, CA) in Tris-Buffered Saline Tween-20
(TBST) for 1 h, and then incubated with primary antibody
overnight at 4°C in either 5% non-fat dry milk or in 5%
BSA. Membranes were subsequently rinsed in TBST, and
then incubated for 1 hour at room temperature with sec-
ondary antibody conjugated with horseradish peroxidase.
After incubation, membranes were rinsed, and antibody
binding was detected with the enhanced chemilumines-
cence system (Amersham).
Immunoprecipitation
Cell pellets were treated with lysis buffer (100 mM Tris-
HCL, 5 μM EDTA and 1% NP-40) containing 1× protease
inhibitor Cocktail and 1× Phosphatase inhibitor cocktail.
Protein concentrations were determined as above. Total
protein (500 μg) were incubated with 5 μg anti-DR5 anti-
body (Axxora, San Diego, CA) at 4°C for 1 h. Protein A/G
beads (Santa Cruz, San Diego, CA) were added to the
lysate and incubated overnight at 4°C with gentle rocking.
The beads were washed 5 × by repeated suspension in 500
μl lysis buffer followed by centrifugation at 10,000 g for
30 s. After the last wash, 50 μl Laemmli buffer (4% SDS,
20% glycerol, 10% 2-mercaptoethanol, 0.004%
bromphenol blue, 0.125 M Tris HCl, pH 6.8) was added
to the pellet and heated at 100°C for 10 min. The samples
were centrifuged again to collect supernatant and then
subjected to Western blot analysis as described above.
Northern blot analysis
Northern hybridization was used to examine the changes
in DR5/DR4 expression level in DAOY cells after HGF
treatment. RNA was isolated using the RNeasy Mini Kit
(Qiagen, Valencia, CA) following the manufacturer's
directions. Oligonucleotide primers were designed as fol-
lows: for DR5 (NM_003842), a 587 bp product was
amplified with primer pair 5'-caccacgaccagaaacacag/5'-
gcctcctcctctgagacctt; for DR4, a 569 bp product was ampli-
fied with primer pair 5'-gctgcaaccatcaaacttca/5'-ttgtgag-
cattgtcctcagc. RT-PCR was conducted using DAOY RNA as
a template and PCR products were subcloned in TOPO
PCR cloning vectors (Invitrogen, Carlsbad, CA) and
sequenced prior to use. Northern blot analysis was per-
formed with 32P-labeled cDNA probes as previously
reported [36]. Radioactivity was quantified by densitome-
try and by phosphorimaging using the Bio-Imaging ana-
lyser BAS 2500 (Fuji Medical Systems; Stamford, CT). All
blots were stripped in 1 × saline sodium citrate buffer
(SSC)/0.1% sodium dodecyl sulfate (SDS) maintained at
a temperature of 85°C for 10 min and then rehybridized
with cDNA specific for 28S rRNA. Results are expressed
relative to 28S rRNA.BMC Cancer 2008, 8:325 http://www.biomedcentral.com/1471-2407/8/325
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Quantitative reverse transcription-PCR (RT-PCR)
Total RNA was extracted from snap-frozen tumor tissue
using Trizol reagent (Invitrogen) via manufacturer's
instructions. RNA was then treated with DNase and fur-
ther purified using the RNeasy protocol (Qiagen). RT-PCR
for tumor necrosis factor receptor superfamily, member
10b (DR5) was done as previously described [37], with all
reactions normalized to actin (Applied Biosystems, Foster
City, CA). Commercially available Assay on Demand Taq-
Man primers and probes were used to measure mRNA for
DR5 (catalog number 4331182). Serial dilution of total
RNA from DAOY was used to generate standard curves.
The expression of c-Met and DR5 in all clinical samples
was calculated in relation to these. Each quantitative RT-
PCR reaction was done in triplicate and error bars repre-
sent SE.
Statistical analysis
Statistical analyses consist of one-way ANOVA followed
by the Tukey multiple comparison tests using Graphpad
Prism (GraphPad, San Diego, CA). Log Pearson analysis
(Graphpad Prism) was used to determine the correlation
between c-Met and DR5 expression in human embryonal
CNS tumors. All experiments reported represent at least
three independent replications. Data are represented as
mean value ± standard error of mean (SE).
Results
HGF enhances TRAIL-induced apoptosis in 
medulloblastoma cells
In the DAOY human medulloblastoma cell line, we found
that HGF sensitizes TRAIL induced apoptotic cell death.
Incubating cells with TRAIL alone (10 ng/ml) for 24 h
induced death in 50% of cells (Fig. 1). HGF (100 ng/ml)
together with TRAIL (10 ng/ml) induced 68% cell death.
Thus, HGF increased the cell death response to TRAIL by
36% (Fig. 1A, P < 0.001, TRAIL+HGF vs TRAIL alone). No
cell death was observed in response to HGF alone. In fact,
incubating DAOY cells with HGF alone (100 ng/ml) for 8
days increased cell numbers by ~40% (Fig. 1B). This is
consistent with our previous observations that HGF
induces cell cycle progression in medulloblastoma cells
including the DAOY cell line [7]. The enhancement of cell
death required that cells be treated with HGF for at least
24 h prior to the addition of TRAIL. Shorter HGF pre-treat-
ment time ranging from 1–6 h failed to significantly
enhance TRAIL induced cell death (Fig. 1C). Thus, HGF
promotes TRAIL induced cell death in a concentration-
and time-dependent manner.
Annexin V-FITC cell staining with flow cytometry analysis
was used to determine if HGF sensitizes DAOY cells to
apoptosis. HGF alone (100 ng/ml) did not alter cell via-
bility (6% annexin V positive cells). Treating cells with 10
ng/ml TRAIL for 24 h increased the proportion of annexin
V positive cells to 32%. Treating cells with HGF for three
days prior to TRAIL treatment increased annexin V posi-
tive cells to 44% (Fig. 1D. P < 0.001 TRAIL+HGF vs. TRAIL
alone), confirming that HGF sensitize these cells to
TRAIL-induced apoptosis.
Apoptotic pathways activated by TRAIL + HGF
We examined the apoptotic pathways induced by TRAIL +
HGF. Cell death induced by TRAIL+HGF was significantly
reversed by either the caspase-8 inhibitor (Z-IETD-FMK,
50 μM) or the caspase-9 inhibitor (Z-LEHD-FMK, 50 μM)
(Fig. 2A). This implicated the involvement of both extrin-
sic and intrinsic apoptosis pathways in the cell death
response. This result was substantiated by the increased
activation of caspase-3, caspase-8, and caspase-9 in cells
treated with both TRAIL + HGF relative to cells treated
with TRAIL alone (Fig. 2B). Furthermore, cleavage of the
pro-apoptotic protein Bid, as evidenced by a decrease in
full-length Bid, was greatest in cells treated with TRAIL +
HGF (Fig. 2B).
Signaling pathways involved in HGF enhanced cell death
C-Met has the potential to complex with and modulate
death receptors independent of its classical tyrosine
kinase driven second messenger responses [14,15]. There-
fore, we asked if the cell death promoting effects of HGF
requires c-Met tyrosine kinase activity. Inhibition of c-Met
activation with PHA-665752 (100 nM) significantly abro-
gated the enhancement of TRAIL-induced cell death by
HGF (Fig. 3A). Thus, the death promoting effect of HGF
requires activation of the c-Met kinase. Western blot anal-
ysis confirmed that c-Met was activated as early as 5
minute after treating DAOY cells with HGF (Fig. 3B) and
this is completely inhibited by PHA-665752.
AKT and ERK are activated downstream of c-Met and are
required for maximizing HGF-induced cell proliferation
and protection against DNA damage agents [7,33]. We
asked if inhibiting these pathways alters the death
enhancing effects of HGF in DAOY cells. The effects of
specific PI3 kinase inhibitors LY294002 (30 μM) and
wortmannin (1 μM) and the specific ERK inhibitor
PD98059 (30 μM) on cell death induced by TRAIL + HGF
were examined. LY294002 and wortmannin alone slightly
induced cell death (80% and 85% cell survival, respec-
tively, vs. control 100%). Both of them increased cell
death induced by HGF+TRAIL (30% and 29% cell sur-
vival, respectively, vs 38% in control), though not statisti-
cally significantly. Treating cells with PD98059 did not
affect cell viability under control conditions, and did not
change the magnitude of cell death induced by
TRAIL+HGF (43% cell survival vs 38% in control, Fig. 3A).
C-jun NH2-terminal kinase (JNK) is also activated by
HGF and contributes to cell death promoted by HGF inBMC Cancer 2008, 8:325 http://www.biomedcentral.com/1471-2407/8/325
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several models [38]. We also examined if JNK is activated
by HGF in DAOY cells and whether JNK activation is
required to sensitize DAOY cells to TRAIL. JNK was
strongly activated by HGF, reaching maximal activation as
early as 5–10 minutes after HGF addition (Fig. 3C). C-Jun,
the down-stream target of JNK, also showed a similar tem-
poral pattern of activation following HGF treatment,
reaching maximal activation in 10 minutes (Fig. 3C).
However, the activated phosphorylated forms of JNK and
c-Jun diminished rapidly, returning to baseline ~1 h after
HGF exposure. Pre-incubating cells for 24 h with the spe-
cific JNK pathway inhibitor CEP-11004 (10 μM) under
conditions that inhibit JNK phosphorylation by ~80%
[39] did not attenuate cell death induced by HGF+TRAIL
(Fig. 3A).
DR5 up-regulation by HGF
The effects of HGF on key regulatory components of the
extrinsic and intrinsic apoptotic pathways were examined
by Western blot analysis. To summarize, total cell levels of
HGF potentiates TRAIL induced apoptosis in DAOY cells Figure 1
HGF potentiates TRAIL induced apoptosis in DAOY cells. A. HGF enhances TRAIL induced cell death in a dose-
dependent manner as measured by MTT assay. TRAIL at 10 ng/ml induced 50% cell loss. Pre-incubation with HGF (100 ng/ml) 
for 72 h resulted in 18% more cell death compare to TRAIL alone. B. HGF alone induces DAOY cell growth. Cells were 
counted every two days after plating with or without HGF in medium containing 10% FBS. HGF promoted cell growth in a 
dose-dependent manner. C. HGF sensitizes TRAIL (3 ng/ml) induced cell death in a time-dependent manner. Pre-incubation 
with HGF for at least 24 h was required to enhance TRAIL-induced cell death. D. FACscan analysis of DAOY cell apoptosis 
using Annexin V-FITC and propidium iodide (PI) staining. Annexin V-positive cells were found to be 6%, 32% and 44% in the 
presence of HGF (100 ng/ml), TRAIL (10 ng/ml) and HGF+TRAIL, respectively. Experiments were repeated three times. Data 
represents mean ± SE (N = 9, * P < 0.001).BMC Cancer 2008, 8:325 http://www.biomedcentral.com/1471-2407/8/325
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the pro-apoptotic protein FADD were diminished slightly
by TRAIL in both control and HGF-treated cells (0.9 and
0.85-fold, respectively). Levels of pro-apoptotic Bim were
decreased by TRAIL in HGF-treated cells only (0.55-fold).
The anti-apoptotic protein Bcl-xl was found to be substan-
tially up-regulated by TRAIL in HGF-treated cells (1.62-
fold). There was no significant change in Bax or FLIP pro-
tein levels (Fig. 4A). Bcl-2 and Bad were not detected in
DAOY cells (data not shown). Thus, HGF does not appear
to sensitize cells to TRAIL by affecting levels of these spe-
cific anti- or pro-apoptotic proteins.
We examined the effect of HGF on the expression of
TRAIL receptors DR4 and DR5. Two isoforms of the DR5,
tumor necrosis factor receptor superfamily member 10b
(TNFRSF10B) gene, have been sequenced in humans.
Northern blot analysis showed a time-dependent increase
in DR5 isoform 1 mRNA expression beginning as early as
1 h after the addition of HGF and reaching a maximum of
~2.5 fold over baseline at 24 h. DR5 isoform 1 mRNA lev-
els remained ~2 fold above baseline 3 days after treating
cells with HGF (Fig. 4B). Isoform 2, which contains a 19
amino acid deletion, was not detected by Northern
hybridization (data not shown).
DR5 up-regulation in response to HGF was further exam-
ined at the protein level by flow cytometry. Cells were
stained with anti-DR5 antibody conjugated with PE and
subjected to flow cytometric analysis. The DR5-positive
cell fraction rose from 61.5% to 83.5% after treating cells
with HGF for 24 hours and the DR5-positive fraction
remained elevated 72 h after treatment (Fig. 5A, B). There
was no or very little expression of DR4 protein in DAOY
cells as detected by flow cytomery; and HGF did not
change the expression of DR4 (data not shown).
We asked if inhibiting HGF:c-Met downstream signaling
pathways including PI3K-AKT and MAPK alters the HGF-
mediated DR5 increase in DAOY cells. Cells were pre-
incubated with different inhibitors for half hour followed
by treatment with HGF for 24 hours. DR5 expression was
measured by Northern blot analysis as mentioned above.
The PI3K-AKT inhibitors LY294002 (30 μM) and wort-
mannin (1 μM) did not affect the DR5 up-regulation
induced by HGF. However, the ERK inhibitor PD98059
(30 μM) blunted up-regulation of DR5 (Fig. 4C, P < 0.05
vs. HGF). This suggests that MAPK pathway may play a
role in HGF-mediated DR5 up-regulation.
We further asked if HGF alters death-inducing signal com-
plex (DISC) formation. DAOY cell protein extracts
obtained 2 h following TRAIL treatment were subjected to
immunoprecipitation with anti-DR5 antibody; precipi-
tated complexes were then analyzed by Western-blot
using antibodies against caspase 8, Flip, FADD and DR5.
Involvement of intrinsic and extrinsic apoptotic pathways in  cell death induced by TRAIL + HGF Figure 2
Involvement of intrinsic and extrinsic apoptotic path-
ways in cell death induced by TRAIL + HGF. A: MTT 
assay showing cytoprotection from specific inhibitors of cas-
pase-8 (Z-IETD, 50 μM) and caspase-9 (Z-LEHD, 50 μM) 
against TRAIL + HGF induced apoptosis. DAOY cells were 
pre-incubated with HGF for 72 h and then treated with cas-
pase inhibitors for 30 min before adding TRAIL. Z-IETD 
reversed cell death induced by TRAIL + HGF completely, 
whereas Z-LEHD protected ~80% of the cells from death. B. 
Western blot analysis of caspase-8, -9, -3 and Bid. Cells were 
treated with or without HGF (100 ng/ml) for 72 h before 
incubation with TRAIL (10 ng/ml) for another 24 h. TRAIL 
alone induced activation (cleavage) of caspase-3, 8, 9 and Bid. 
HGF enhanced the activation of caspases and Bid by TRAIL. 
Experiments were repeated three times (N = 9, * P < 0.001).BMC Cancer 2008, 8:325 http://www.biomedcentral.com/1471-2407/8/325
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Signaling pathways mediating the potentiation of TRAIL-induced cell death by HGF Figure 3
Signaling pathways mediating the potentiation of TRAIL-induced cell death by HGF. A. DAOY cells were pre-
incubated with or without inhibitors for 30 min, and then treated with HGF for 72 h followed by TRAIL for 24 h. Cell viability 
was analyzed by MTT assay. The c-Met inhibitor PHA-665752 (100 nM) significantly reduced the cell death promoting effect of 
HGF. The PI3 kinase inhibitor LY294002 (30 μM) or wortmannin (1 μM) slightly increased the cell death rate induced by TRAIL 
+ HGF. The ERK inhibitor PD98059 (30 μM) as well as the JNK pathway inhibitor CEP-11004 (10 μM) had no effect on the cell 
death induced by TRAIL + HGF. B. DAOY cells were pre-incubated with c-Met inhibitor PHA-665752 (100 nM) for 30 min 
before adding HGF. Phosphorylation of c-Met in cells treated with HGF or HGF+TRAIL was inhibited by PHA-665752. C. 
Western blot analysis with anti-JNK and anti-phospho-JNK (Ser 198) antibodies was used to determine JNK activation. In 
DAOY cells, HGF induced JNK activation as early as 5 min and lasted for 30 min. C-Jun was also activated within 10 min of 
HGF treatment. Data represent mean ± SE (N = 9, * P < 0.001).BMC Cancer 2008, 8:325 http://www.biomedcentral.com/1471-2407/8/325
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All of these DISC components were increased in HGF +
TRAIL treated cells (Fig. 5C). In contrast, c-Met was not co-
precipitated with DR5, indicating no direct interaction
between c-Met and DR5 (Fig. 5C), further supporting our
finding that c-Met enhances DR5 expression at the tran-
scriptional level.
Expression of DR5 and c-Met in human embryonal tumors
Moreover, we asked if DR5 increase by HGF in the DAOY
cell line reflects a relationship between DR5 and the
HGF:c-Met pathway in human embryonal CNS tumors.
RT-PCR was used to measure the levels of c-Met and DR5
mRNA in 18 snap-frozen human embryonal tumor speci-
mens (14 medulloblastoma and 4 peripheral neuroecto-
dermal tumors (PNET)). Of the 18 tumor samples tested,
all contained detectable levels of c-Met and DR5 mRNA.
The expression level of c-Met is from 0.5 to 68.4 (c-Met/
actin, normalized to DAOY). The expression level of DR5
in the 18 tumor samples ranges from 1.0–98.5 (DR5/
actin, normalized to DAOY). In normal brain tissue the
expression level of c-Met and DR5 is 0.45 and 2.4, respec-
tively. DR5 and c-Met do show a moderate positive corre-
lation (r = 0.4, P = 0.06, Log Pearson analysis) (Fig. 6A).
This relationship is best depicted after the 18 tumor spec-
imens were independently divided into three groups each
containing 6 tumors based on c-Met expression levels
(highest, middle, and lowest thirds) and similarly into
three groups based on DR5 expression levels. Of the 6
tumors with highest c-Met expression, 50% were among
the highest and 17% were among the lowest DR5 express-
ers, respectively. In contrast, of the 6 tumors with lowest
c-Met expression, 17% were among the highest and 50%
were among the lowest DR5 expressers, respectively (Fig.
Figure 4
Modulation of pro- and anti-apoptotic proteins by HGF Figure 4
Modulation of pro- and anti-apoptotic proteins by 
HGF. A. Western blot analysis of FADD, FLIP, Bax, Bcl-xl 
and Bim protein levels in response to HGF, TRAIL and HGF 
+ TRAIL. Cells were treated with HGF for 72 h before incu-
bation with TRAIL for another 24 h. FADD and Bim were 
slightly down regulated by HGF + TRAIL. B. Northern blot 
analysis of DR5 mRNA levels in response to HGF. DAOY 
cells were treated with HGF for the indicated times. Total 
cell RNA was hybridized with probes for DR5 and 28S RNA 
(control) as described in Materials and Methods. DR5 iso-
form 1 mRNA levels were increased between 1–72 h as 
shown (* P < 0.001). C. DAOY cells were pre-incubated with 
inhibitors for 30 min, and then treated with HGF for 24 h fol-
lowed by Northern blot analysis for DR5 expression. The 
PI3K inhibitor LY294002 (30 μM) or wortmannin (1 μM) did 
not affect the DR5 up-regulation induced by HGF. The 
MAPK inhibitor PD98059 (30 μM) reversed up-regulation of 
DR5 by HGF (# P < 0.05). Data represent mean ± SE (N = 
6).BMC Cancer 2008, 8:325 http://www.biomedcentral.com/1471-2407/8/325
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6B). This trend suggests that HGF:c-Met pathway activity
influences DR5 expression and may in turn influence
TRAIL induced cell death in human embryonal cell malig-
nancies.
Discussion
We show that HGF promotes TRAIL-induced cell death in
the human medulloblastoma DAOY cell line. We impli-
cate a mechanism by which activating the c-Met tyrosine
kinase enhances DR5 death receptor expression, resulting
in enhanced DISC formation and downstream effector
caspase-dependent apoptosis in response to TRAIL. This
is, to the best of our knowledge, the first study demon-
strating up-regulation of DR5 by the HGF:c-Met signaling
pathway. We also identify a relationship between c-Met
and DR5 expression level in clinical brain tumor speci-
mens, suggesting that our in vitro findings may be trans-
latable to a subset of human embryonal CNS tumors.
HGF is well known for its ability to protect tumor cell
death triggered by various DNA-damaging stimuli includ-
ing gamma-radiation and chemotherapeutic agents [10-
13]. We reported previously that HGF protects DAOY
medulloblastoma cells against chemotherapy-induced
apoptosis [7]. MacDonald and colleagues have compared
the gene expression patterns of medulloblastoma cell
lines to medulloblastoma clinical specimens and con-
cluded that DAOY cells most closely mimic metastatic
medulloblastoma, supporting the potential relevance of
our in vitro results [40]. The potential that our apoptosis-
promoting results might be more broadly applicable to
human medulloblastoma is further supported by the cor-
relation between c-Met and DR5 expression level in
human embryonal CNS tumors. The cell specific molecu-
lar determinants of pro- and anti-apoptosis responses to Figure 5
HGF increases the DR5 expression and enhances TRAIL- induced DISC formation Figure 5
HGF increases the DR5 expression and enhances 
TRAIL-induced DISC formation. A. FACScan analysis of 
DR5 expression in DAOY cell surface after HGF treatment. 
Cells treated with HGF for 24 – 72 h were incubated with 
PE-conjugated anti-DR5 antibody for 30 min. Mouse IgG was 
used as negative control. At baseline ~61.5% cells were DR5 
positive. After 24 h incubation with HGF, the DR5 positive 
pool increased to 83.5%. B. Compared to control, there was 
a significant increase in DR5 positive cells after 24 – 72 h 
incubation with HGF (N = 6, * P < 0.05). C. DAOY cells 
were pre-treated with HGF for 72 h followed by TRAIL for 2 
h. Equal amounts of total cell protein (500 μg) were immuno-
precipitated with anti-DR5 antibody and then subjected to 
Western blot analysis with antibodies to caspase 8, FLIP, 
FADD, c-Met and DR5 antibody. There was a distinct 
increased in DISC in cells treated with TRAIL + HGF.BMC Cancer 2008, 8:325 http://www.biomedcentral.com/1471-2407/8/325
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Relationship between c-Met and DR5 expression in human embryonal CNS tumors Figure 6
Relationship between c-Met and DR5 expression in human embryonal CNS tumors. A. Quantitative reverse tran-
scription-PCR results showing the expression levels of c-Met and DR5 relative to actin in 18 snap-frozen tissues samples. The 
expression of c-Met and DR5 in all samples was calculated in relation to DAOY expression. B. We assigned tumors to either 
high (upper third), median (middle third) and low (lowest third) c-Met expression or TRAIL expression (N = 6 per group). Of 
the 6 tumors expressing high c-Met (H-cMet), 50% expressed high DR5. Of the 6 tumors expressing low c-Met (L-cMet), 50% 
expressed low level of DR5. The correlation between c-Met expression and DR5 expression is 0.4 (P = 0.06, Log Pearson anal-
ysis).BMC Cancer 2008, 8:325 http://www.biomedcentral.com/1471-2407/8/325
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HGF:c-Met pathway activation are of interest and will
require further investigation.
The second messenger pathways downstream of c-Met
activation are multifunctional and can include cytoprotec-
tion, proliferation or death promotion [11,14,36,38]. The
PI3K-AKT pathway, which is potently activated by HGF,
mediates cell protection in a large number of in vitro
models. In DAOY cells, the overall effect of c-Met activa-
tion was to enhance TRAIL-induced death. We used the
PI3K specific inhibitors LY294002 and wortmannin to
specifically examine the role of PI3K-AKT pathway activity
in the sensitivity of HGF-treated DAOY cells to TRAIL.
While not statistically significant, we found that both
inhibitors increased TRAIL-induced cell death in HGF-
treated cells. Thus, it is possible that PI3K-AKT pathway
activation by HGF:c-Met signaling does have cytoprotec-
tive actions against in TRAIL-induced DAOY cell apopto-
sis even though the predominant effect of c-Met activation
is death promoting under our experimental conditions.
Things become more complicated when the cells were
pre-treated with the MAPK specific inhibitor PD98059.
Similar as PI3K-AKT, MAPK play an important role in
cytoprotection (6, 7). Our Northern blot analysis data
showed that MAPK may also mediate the DR5 up-regula-
tion induced by HGF. The two aspects of MAPK may
counteract and this may explain that the net effect of
PD98059 is neutral. The JNK (c-jun NH2-terminal
kinase), a well known cell death promoting signaling
pathway, was found to be activated by HGF and to medi-
ate HGF-induced cell death in other tumor models [38].
We found that in DAOY cells, JNK was transiently acti-
vated by HGF, peaking within 1 hour, and then quickly
returned to base line. It has been postulated that sustained
JNK activation is required to activate death-promoting
downstream targets such as Bim and Bak [41]. The fact
that JNK was only transiently activated by HGF is consist-
ent with at most a minor role of JNK in sensitizing DAOY
cells to TRAIL induced apoptosis. The fact that the JNK
pathway specific inhibitor CEP-11004 failed to reverse the
death promoting effect of HGF further supports the
notion that sustained JNK activation is required to pro-
mote apoptosis.
C-Met activation by HGF can inhibit Fas-induced hepato-
cyte apoptosis by preventing the degradation of FLIPL in
response to activated Fas [15]. In contrast to this, we
found that c-Met activation does not modulate FLIPL lev-
els in DAOY cells treated with TRAIL. Whether or not HGF
affects FLIP function via other mechanisms will require
further investigation. Complex formation between c-Met
and the death receptor Fas has been found in other cell
lines [14,19]. In these reports, the interaction between c-
Met and Fas was found to inhibit DISC formation and
thereby protected cells from apoptosis. Based on these
reports, it is possible that HGF might dissociate c-Met
from TRAIL receptors and thereby promote TRAIL-
induced cell death [19]. However, co-immunoprecipita-
tion experiments did not detect complexes with c-Met and
DR5, the predominant TRAIL receptor expressed by
DAOY cells. Instead, HGF was found to upregulate DR5
expression and increase the formation of death-inducing
signaling complexes containing DR5 and caspase-8. Over-
all, our findings suggest that DR5 enhancement is the pre-
dominant mechanism by which HGF potentiates TRAIL-
induced cell death in DAOY cells.
Conclusion
In conclusion, we have demonstrated for the first time
that c-Met kinase activity can up-regulate death receptor
expression and thereby sensitize tumor cells to the death
receptor ligand TRAIL. Our analysis of clinical specimens
suggests a correlation between c-Met and DR5 expression
level in a subset of human embryonal CNS malignancies.
These findings extend the notion that the c-Met receptor
tyrosine kinase can have dual anti-apoptotic and pro-
apoptotic actions in a common pediatric brain malig-
nancy. Our findings suggest that death receptor activation
may provide a route to overcome chemo/radio-resistant
cells in subsets of embryonal CNS malignancies that
express an activated c-Met pathway.
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